Your Health After Treatment: Long-Term Care
At a Glance
After ovarian hyperthecosis treatment, normal testosterone does not always reverse diabetes, high blood pressure, cholesterol problems, or uterine risks. Ongoing metabolic screening, hormone checks, and prompt evaluation of postmenopausal bleeding remain important.
Finding out that your testosterone levels have normalized after treatment is a major milestone. However, it is important to view this as the start of a new chapter in your health management, rather than the end of the story. While the source of the hormones may be gone, the “metabolic footprint” that hyperthecosis often leaves behind requires its own individualized, ongoing attention [1][2].
The Reality of Metabolic Health
A common hope for patients is that once the ovaries are removed and testosterone drops, the related issues like weight gain or diabetes will also disappear. However, research indicates that this is not guaranteed for every patient [1].
In studies of women who had surgery for hyperthecosis, researchers found that markers like BMI (body mass index), HbA1c (blood sugar over time), and cholesterol levels did not significantly improve on their own—even two years after surgery [1]. Because conditions like type 2 diabetes and high blood pressure are complex and long-lasting, they typically require ongoing management through:
- Continued Medication: You may still need to take medications for blood pressure, cholesterol, or blood sugar (such as metformin) even after your testosterone is back to a normal range, if a clinician determines you still have an ongoing indication [3][4].
- Coordinated Care: It is essential to work with a primary care doctor or an endocrinologist who understands that your metabolic risks may persist even after the hormonal “engine” is gone [4]. Follow-up decisions should be individualized.
Protecting the Uterine Lining
A lesser-known risk of ovarian hyperthecosis involves the endometrium, which is the lining of the uterus. When your body has very high levels of testosterone, some of that hormone can be converted into estrogen through a process called peripheral aromatization [5][6].
In postmenopausal women, this extra estrogen can act on the uterus without the “balance” of progesterone, which can lead to:
- Endometrial Hyperplasia: A condition where the lining of the uterus becomes too thick [6][7].
- Endometrial Polyps: Small, non-cancerous growths on the uterine lining [6].
- Increased Association with Cancer: Research has found that hyperthecosis is more common in women who also have endometrioid adenocarcinoma (a type of uterine cancer) [6][8]. This is an association, not a prediction that you will develop cancer.
What this means for you: If you have not had a hysterectomy (removal of the uterus), your doctor should carefully evaluate your uterine health. This often involves a transvaginal ultrasound to measure the thickness of the lining. If you experience any postmenopausal vaginal bleeding, an endometrial thickness greater than 4 millimeters commonly leads to an endometrial biopsy to rule out precancerous or cancerous changes [9][10]. (An incidentally thickened endometrium in someone without bleeding is evaluated based on individualized risk factors rather than automatically requiring a biopsy).
Long-Term Monitoring Checklist
Even after successful treatment, your medical team will likely want to keep an eye on several key areas of your health, tailored to your specific situation [11][1]:
- Hormone Checks: Periodic blood tests may be used to ensure testosterone stays within the normal range. If levels start to rise again, it could signal a need for further investigation [11][12].
- Symptom Tracking: Keep a log of whether symptoms like hair growth or thinning are improving. While the progression should stop, existing changes may take a long time to reverse [5].
- Metabolic Screening: Regular checks of your blood pressure, HbA1c, and lipid (cholesterol) panels, depending on your comorbidities [1].
- Vigilance for Bleeding: Any vaginal bleeding or spotting after menopause—even a tiny amount—should be reported to your doctor immediately [9].
By staying proactive about your metabolic and uterine health, you can manage the long-term effects of hyperthecosis and focus on your overall well-being.
Common questions in this guide
Will my diabetes, blood pressure, or cholesterol problems go away after hyperthecosis treatment?
Do I still need metformin or other medicines after my testosterone normalizes?
Why does ovarian hyperthecosis treatment require monitoring of the uterine lining?
What should I do if I have bleeding or spotting after menopause?
How often should testosterone and metabolic health be checked after treatment?
How long can hair growth or hair thinning take to improve after treatment?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Since my metabolic risks might persist after surgery, how will we coordinate my ongoing cardiovascular and diabetes screening?
- 2.What was the endometrial thickness on my most recent ultrasound, and what does that mean for me right now?
- 3.If I experience any spotting or bleeding, how quickly should I schedule an endometrial evaluation?
- 4.Should I continue taking metformin or my blood pressure medications now that my testosterone has normalized?
- 5.How frequently should we monitor my hormone levels or metabolic markers moving forward?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (12)
- 1
Persistent Poor Metabolic Profile in Postmenopausal Women With Ovarian Hyperandrogenism After Testosterone Level Normalization.
Rocha T, Crespo RP, Yance VVR, et al.
Journal of the Endocrine Society 2019; (3(5)):1087-1096 doi:10.1210/js.2018-00405.
PMID: 31073547 - 2
Clinical Case Seminar: Postmenopausal androgen excess-challenges in diagnostic work-up and management of ovarian thecosis.
Mamoojee Y, Ganguri M, Taylor N, Quinton R
Clinical endocrinology 2018; (88(1)):13-20 doi:10.1111/cen.13492.
PMID: 28980338 - 3
Ovarian Hyperthecosis Presenting With Postmenopausal Virilization and New-Onset Type 2 Diabetes.
Knott JA, Morris J
JCEM case reports 2025; (3(7)):luaf118 doi:10.1210/jcemcr/luaf118.
PMID: 40443457 - 4
Hyperandrogenism and Cardiometabolic Risk in Pre- and Postmenopausal Women-What Is the Evidence?
Hirschberg AL
The Journal of clinical endocrinology and metabolism 2024; (109(5)):1202-1213 doi:10.1210/clinem/dgad590.
PMID: 37886900 - 5
A benign cause of hyperandrogenism in a postmenopausal woman.
Roque JJN, Alves IBS, Rodrigues AMAPF, Bugalho MJ
Endocrinology, diabetes & metabolism case reports 2021; (2021()).
PMID: 33597312 - 6
Association of ovarian hyperthecosis with endometrial polyp, endometrial hyperplasia, and endometrioid adenocarcinoma in postmenopausal women: a clinicopathological study of 238 cases.
Zhang C, Sung CJ, Quddus MR, et al.
Human pathology 2017; (59()):120-124 doi:10.1016/j.humpath.2016.09.021.
PMID: 27746268 - 7
Severe hyperandrogenemia in postmenopausal woman as a presentation of ovarian hyperthecosis. Case report and mini review of the literature.
Czyzyk A, Latacz J, Filipowicz D, et al.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2017; (33(11)):836-839 doi:10.1080/09513590.2017.1337094.
PMID: 28604129 - 8
Ciliated Carcinoma of the Endometrium.
Guerrieri C, Anderson P, Hudacko R
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2021; (40(2)):141-147 doi:10.1097/PGP.0000000000000686.
PMID: 32897959 - 9
Diagnosis and Management of Endometrial Cancer.
Braun MM, Overbeek-Wager EA, Grumbo RJ
American family physician 2016; (93(6)):468-74.
PMID: 26977831 - 10
Long-term risk of endometrial cancer following postmenopausal bleeding and reassuring endometrial biopsy.
Visser NC, Sparidaens EM, van den Brink JW, et al.
Acta obstetricia et gynecologica Scandinavica 2016; (95(12)):1418-1424 doi:10.1111/aogs.13022.
PMID: 27633936 - 11
Ovarian stromal hyperthecosis: An underestimated virilizing disorder in postmenopausal women.
Boudaouara O, Sellami A, Roger P
Annales d'endocrinologie 2025; (86(5)):101800 doi:10.1016/j.ando.2025.101800.
PMID: 40513985 - 12
Approach to Investigation of Hyperandrogenism in a Postmenopausal Woman.
Hirschberg AL
The Journal of clinical endocrinology and metabolism 2023; (108(5)):1243-1253 doi:10.1210/clinem/dgac673.
PMID: 36409990
This page is for informational purposes only and does not constitute medical advice. Your gynecologist, endocrinologist, or primary care clinician can tailor hormone, metabolic, and uterine follow-up to your situation.
Get notified when new evidence is published on ovarian stromal hyperthecosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.